DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer

Human Gene Therapy

Volumn 20, Issue 11, 2009, Pages 1269-1278

  Low, Lindsey ^a   Mander, Ann ^a   McCann, Katy ^a   Dearnaley, David ^b   Tjelle, Torunn ^c   Mathiesen, Iacob ^c   Stevenson, Freda ^a   Ottensmeier, Christian H ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Inovio AS   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; PROSTATE SPECIFIC ANTIGEN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; IMMUNOGLOBULIN G; MEMBRANE ANTIGEN; PEPTIDE FRAGMENT; PRIMER DNA; TETANUS TOXIN; TETANUS TOXIN (947-966);

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG SAFETY; ELECTROPORATION; HUMAN; HUMORAL IMMUNITY; INJECTION SITE PAIN; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; ADVERSE DRUG REACTION; BLOOD; CROSSOVER PROCEDURE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; PROCEDURES; PROSTATE TUMOR; VACCINATION;

ANTIGENS, SURFACE; CROSS-OVER STUDIES; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOGLOBULIN G; MALE; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; TETANUS TOXIN; VACCINATION; VACCINES, DNA;

EID: 70350128929     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.067     Document Type: Article

References (37)

1. Ahlen, G., Soderholm, J., Tjelle, T., Kjeken, R., Frelin, L., Ho-glund, U., Blomberg, P., Fons, M., Mathiesen, I., and Sallberg, M. (2007). In vivo electroporation enhances the immunoge-nicity of hepatitis C virus nonstructural 3=4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J. Immunol. 179, 4741-4753.
2. Aihara, H., and Miyazaki, J. (1998). Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16, 867-870.
3. Buchan, S., Gronevik, E., Mathiesen, I., King, C.A., Stevenson, F.K., and Rice, J. (2005). Electroporation as a ''prime=boost'' strategy for naked DNA vaccination against a tumor antigen. J. Immunol. 174, 6292-6298.
4. Daud, A.I., Deconti, R.C., Andrews, S., Urbas, P., Riker, A.I., Sondak, V.K., Munster, P.N., Sullivan, D.M., Ugen, K.E., Messina, J.L., and Heller, R. (2008). Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 26, 5896-58903.
5. Di Genova, G., Roddick, J., Mcnicholl, F., and Stevenson, F.K. (2006). Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific. Blood 107, 2806-2813.
6. Drape, R.J., Macklin, M.D., Barr, L.J., Jones, S., Haynes, J.R., and Dean, H.J. (2006). Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24, 4475-4481.
7. Dupuis, M., Denis-Mize, K., Woo, C., Goldbeck, C., Selby, M.J., Chen, M., Otten, G.R., Ulmer, J.B., Donnelly, J.J., Ott, G., and McDonald, D.M. (2000). Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J. Immunol. 165, 2850-2858.
8. Gronevik, E., Mathiesen, I., and Lomo, T. (2005). Early events of electroporation-mediated intramuscular DNA vaccination potentiate Th1-directed immune responses. J. Gene Med. 7, 1246-1254.
9. Hirao, L.A., Wu, L., Khan, A.S., Satishchandran, A., Draghia-Akli, R., and Weiner, D.B. (2008). Intradermal=subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26, 440-448.
10. Ishii, K.J., Kawagoe, T., Koyama, S., Matsui, K., Kumar, H., Kawai, T., Uematsu, S., Takeuchi, O., Takeshita, F., Coban, C., and Akira, S. (2008). TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451, 725-729.
11. Kjeken, R., Tjelle, T.E., Kvale, D., and Mathiesen, I. (2004). Clinical evaluation of pain and muscle damage induced by electroporation of skeletal muscle in humans [abstract 157]. Mol. Ther. 9, S60.
12. Laddy, D.J., Yan, J., Khan, A.S., Andersen, H., Cohn, A., Greenhouse, J., Lewis, M., Manischewitz, J., King, L.R., Golding, H., Draghia-Akli, R., and Weiner, D.B. (2009). Elec-troporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J. Virol. 83, 4624-4630.
13. Liu, J., Kjeken, R., Mathiesen, I., and Barouch, D.H. (2008). Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J. Virol. 82, 5643-5649.
14. Lu, J., and Celis, E. (2002). Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res. 62, 5807-5812.
15. Luckay, A., Sidhu, M.K., Kjeken, R., Megati, S., Chong, S.Y., Roopchand, V., Garcia-Hand, D., Abdullah, R., Braun, R., Montefiori, D.C., Rosati, M., Felber, B.K., Pavlakis, G.N., Mathiesen, I., Israel, Z.R., Eldridge, J.H., and Egan, M.A. (2007). Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol. 81, 5257-5269.
16. Mander, A., Chowdhury, F., Low, L., and Ottensmeier, C.H. (2009). Fit for purpose? A case study: Validation of immuno-logical endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. Cancer Immunol. Immunother. 58, 789-800.
17. Mathiesen, I. (1999). Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther. 6, 508-514.
18. Mathiesen, I., and Lømo, T. (1998). Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle. U.S. Patent 6,110,161, August 29, 2000 (http:= = www. freepatentsonline.com=6110161.html).
19. Mir, L.M., Bureau, M.F., Rangara, R., Schwartz, B., and Scher-man, D. (1998). Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. C.R. Acad. Sci. III 321, 893-899.
20. O'Hagan, D.T., Singh, M., and Ulmer, J.B. (2006). Microparticle-based technologies for vaccines. Methods 40, 10-19.
21. Otten, G., Schaefer, M., Doe, B., Liu, H., Srivastava, I., Zur Me-gede, J., O'Hagan, D., Donnelly, J., Widera, G., Rabussay, D., Lewis, M.G., Barnett, S., and Ulmer, J.B. (2004). Enhancement of DNA vaccine potency in rhesus macaques by electropora-tion. Vaccine 22, 2489-2493.
22. Otten, G.R., Schaefer, M., Doe, B., Liu, H., Megede, J.Z., Donnelly, J., Rabussay, D., Barnett, S., and Ulmer, J.B. (2006). Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 24, 4503-4509.
23. Parker, C.C., and Dearnaley, D.P. (1998). The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother. Oncol. 49, 103-110.
24. Rice, J., Elliott, T., Buchan, S., and Stevenson, F.K. (2001). DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: Implications for cancer vaccines. J. Immunol. 167, 1558-1565.
25. Rice, J., Ottensmeier, C.H., and Stevenson, F.K. (2008). DNA vaccines: Precision tools for activating effective immunity against cancer. Nat. Rev. Cancer 8, 108-120.
26. Rols, M.P. (2006). Electropermeabilization, a physical method for the delivery of therapeutic molecules into cells. Biochim. Bio-phys. Acta 1758, 423-428.
27. Scheerlinck, J.P., Karlis, J., Tjelle, T.E., Presidente, P.J., Mathie-sen, I., and Newton, S.E. (2004). In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 22, 1820-1825.
28. Silver, D.A., Pellicer, I., Fair, W.R., Heston, W.D., and Cordon-Cardo, C. (1997). Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81-85.
29. Soto, D.E., Andridge, R.R., Pan, C.C., Williams, S.G., Taylor, J.M., and Sandler, H.M. (2008). In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free interval. Int. J. Radiat. Oncol. Biol. Phys. 71, 1295-1301.
30. Swartz, M., Eberhart, J., Mastick, G.S., and Krull, C.E. (2001). Sparking new frontiers: Using in vivo electroporation for genetic manipulations. Dev. Biol. 233, 13-21.
31. Tjelle, T.E., Salte, R., Mathiesen, I., and Kjeken, R. (2006). A novel electroporation device for gene delivery in large animals and humans. Vaccine 24, 4667-4670.
32. Tollefsen, S., Vordermeier, M., Olsen, I., Storset, A.K., Reitan, L.J., Clifford, D., Lowrie, D.B., Wiker, H.G., Huygen, K., Hewinson. G., Mathiesen I., Tjelle T.E. 2003 DNA injection in combination with electroporation: A novel method for vaccination of farmed ruminants. Scand. J. Immunol 57 229-238
33. Ulmer, J.B., Wahren, B., and Liu, M.A. (2006). Gene-based vaccines: Recent technical and clinical advances. Trends Mol. Med. 12, 216-222.
34. Wang, S., Zhang, C., Zhang, L., Li, J., Huang, Z., and Lu, S. (2008). The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 26, 2100-2110.
35. Widera, G., Austin, M., Rabussay, D., Goldbeck, C., Barnett, S.W., Chen, M., Leung, L., Otten, G.R., Thudium, K., Selby M.J., and Ulmer, J.B. (2000). Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 164, 4635-4640. (Pubitemid 30238062)
36. Wloch, M.K., Smith, L.R., Boutsaboualoy, S., Reyes, L., Han, C., Kehler, J., Smith, H.D., Selk, L., Nakamura, R., Brown, J.M., Marbury, T., Wald, A., Rolland, A., Kaslow, D., Evans, T., and Boeckh, M. (2008). Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J. Infect. Dis. 197, 1634-1642.
37. Zucchelli, S., Capone, S., Fattori, E., Folgori, A., Di Marco, A., Casimiro, D., Simon, A.J., Laufer, R., La Monica, N., Cortese R., and Nicosia, A. (2000). Enhancing B-and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J. Virol. 74, 11598-115607